NCT03687554View on ClinicalTrials.gov

Effect of Venglustat in Patients With Renal Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 5, 2018

Primary Completion Date

February 27, 2019

Study Completion Date

February 27, 2019

Conditions
Healthy VolunteersPolycystic Kidney, Autosomal Dominant
Interventions
DRUG

Venglustat GZ/SAR402671

Pharmaceutical form: Hard Capsule Route of administration: Oral

Trial Locations (1)

33014

Investigational Site Number 8400001, Miami

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT03687554 - Effect of Venglustat in Patients With Renal Impairment | Biotech Hunter | Biotech Hunter